SCHEMBL2563308

SCHEMBL2563308

COCC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1

nearest known ligand 0.75

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
GRK2 P25098 18/20 0.75
ROCK1 Q13464 14/20 0.75
GRK5 P34947 14/20 0.75
RPS6KB1 P23443 2/20 0.75
RPS6KA1 Q15418 2/20 0.75
GRK1 Q15835 6/20 0.57
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2566962 0.90 GRK2 (0.78) GRK2ROCK1GRK5RPS6KB1RPS6KA1
SCHEMBL2562906 0.89 GRK2 (0.76) GRK2ROCK1GRK5RPS6KB1RPS6KA1
Gsk-180736A SCHEMBL2569804 0.86 GRK2 (1.00) GRK2ROCK1GRK5RPS6KB1RPS6KA1
Gsk-180736A SCHEMBL29431133 0.86 GRK2 (1.00) GRK2ROCK1GRK5RPS6KB1RPS6KA1
SCHEMBL2563081 0.84 GRK2 (0.69) GRK2ROCK1GRK5RPS6KB1RPS6KA1
SCHEMBL2570028 0.83 GRK2 (0.94) GRK2ROCK1GRK5RPS6KB1RPS6KA1
SCHEMBL2563742 0.83 GRK2 (0.78) GRK2ROCK1GRK5RPS6KB1RPS6KA1
SCHEMBL2567572 0.82 GRK2 (0.63) GRK2ROCK1GRK5RPS6KB1RPS6KA1
SCHEMBL2570395 0.79 GRK2 (0.84) GRK2ROCK1GRK5RPS6KB1RPS6KA1
SCHEMBL2568919 0.78 GRK2 (0.70) GRK2ROCK1GRK5RPS6KB1RPS6KA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 EP claimed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US claimed
EP-1633740-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-11-19 EP claimed
JP-2007516173-A 2007-06-21 JP claimed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US claimed
EP-1633740-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2006-03-15 EP claimed
WO-2004112719-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-29 WO claimed
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 EP disclosed
EP-1633740-B1 5-(ACYLAMINO)INDAZOLE DERIVATIVES AS KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-11-09 EP disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
US-7560467-B2 Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-07-14 US disclosed
EP-1633740-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2008-11-19 EP disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
US-20070099944-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2007-05-03 US disclosed
EP-1633740-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2006-03-15 EP disclosed
WO-2004112719-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099944-A1 Chemical compounds ROCK1, ROCK2, CIT GRK2 165/4885ROCK1 1/4885GRK5 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.